Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Disruptive Pharma ABOSTO:DPHA +0.83%4 Net Cash per Share is kr1.32 as of Jun. 2026. GuruFocus rates OSTO:DPHA with a GF Score™ of 4/100. Among 256 Drug Manufacturers companies, Disruptive Pharma AB ranks worse than 60.55% on this metric.
The historical rank and industry rank for Disruptive Pharma AB's Net Cash per Share or its related term are showing as below:
OSTO:DPHA'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0 Med: 0 Max: 14
Current: 12.1
During the past 13 years, the highest Price-to-Net-Cash Ratio of Disruptive Pharma AB was 14.00. The lowest was 0.00. And the median was 0.00.
OSTO:DPHA's Price-to-Net-Cash is ranked worse than 60.55% of 256
companies
in the Drug Manufacturers industry
Industry Median: 9.155
vs OSTO:DPHA: 12.10
Disruptive Pharma AB (OSTO:DPHA) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Disruptive Pharma AB Net Cash per Share Related Terms
Disruptive Pharma AB Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Disruptive Pharma AB's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Disruptive Pharma AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Disruptive Pharma AB Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Disruptive Pharma AB's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Disruptive Pharma AB's Price-to-Net-Cash falls into.
Disruptive Pharma AB Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Disruptive Pharma AB's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Disruptive Pharma AB (OSTO:DPHA) has a Net Cash per Share of kr1.32 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Disruptive Pharma AB and its competitors. According to the industry distribution chart, Disruptive Pharma AB ranks #155 out of 256 companies in the Drug Manufacturers industry, placing it in the top 60.5%.
Is Disruptive Pharma AB's Net Cash per Share too high?
Disruptive Pharma AB's current Net Cash per Share is kr1.32. Based on the distribution chart, Disruptive Pharma AB ranks #155 out of 256 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Disruptive Pharma AB has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Disruptive Pharma AB's Net Cash per Share compare to ?
According to the Drug Manufacturers industry distribution chart, Disruptive Pharma AB ranks #155 out of 256 companies for Net Cash per Share. This places Disruptive Pharma AB in the lower half of its industry. The industry median Net Cash per Share is 9.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 9.16, based on 256 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Disruptive Pharma AB and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 9.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Disruptive Pharma AB's current Net Cash per Share is kr1.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disruptive Pharma AB stock overvalued right now?
Disruptive Pharma AB (OSTO:DPHA) has a current Net Cash per Share of kr1.32. The current Net Cash per Share is kr1.32. Disruptive Pharma AB's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Disruptive Pharma AB (OSTO:DPHA), the current Net Cash per Share is kr1.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Disruptive Pharma AB is a Swedish drug delivery technology company developing and commercializing Formulite, a patented platform based on mesoporous magnesium carbonate (MMC). The platform is designed to improve the solubility, oral bioavailability and other properties of pharmaceutical compounds. The company's business model is based on contract development, partnerships and licensing arrangements with pharmaceutical and biotechnology companies for the development and commercialization of drug products optimized with Formulite.
4GF Score
Get the complete analysis for OSTO:DPHA
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:DPHA has been successfully added to your 
